ResMed (NYSE: RMD) reported Q2 EPS of $0.73, $0.03 better than the analyst estimate of $0.70. Revenue for the quarter came in at $530.4 million versus the consensus estimate of $515.94 million.

"We had a strong quarter with 18 percent constant currency revenue growth led by solid growth in our Brightree software offerings and global device sales," said Mick Farrell, ResMed's CEO

For earnings history and earnings-related data on ResMed (RMD) click here.